Alejandro García-Castaño
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alejandro García-Castaño has a total of 95 co-authors. Here are the top co-authors by number of shared publications:
- Leire Madariaga
Pediatric Nephrology Department, Cruces University Hospital, Barakaldo, Spain
10 shared publications - Gema Ariceta
Hospital Vall d'Hebron, Barcelona, Spain
5 shared publications Gustavo Pérez de Nanclares
Affiliation Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, CIBERDEM, CIBERER, Bizkaia, Spain
3 shared publications- Luis Castaño
Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28029 Madrid, Spain
3 shared publications Rosa Martínez
Affiliation Biocruces Bizkaia Health Research Institute, CIBERDEM, CIBERER, Bizkaia, Spain
3 shared publications- Ainhoa Camille Aranaga-Decori
University of the Basque Country (EHU), Leioa, Spain
2 shared publications
Latest Publications
- Open Access
- 10 August 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2249-2262
Type, Location, and Zygosity of KCNJ16 Variants May Determine the Clinical Severity of Hypokalemia Tubulopathy and Deafness
Key Points: KCNJ16 variants cause clinically heterogeneous hypokalemic tubulopathy with variable onset, severity of acidosis, and possible sensorineural deafness. Pathogenic variants affect heteromerization, membrane trafficking, and activity of the resulting channels on the basis of the type and location of the variant. Background: The pivotal role of K ir 5.1 ( KCNJ16 ) in maintaining electrolyte and acid–base homeostasis has been demonstrated in animal studies and highlighted by the identification of disease-causing variants in KCNJ16 resulting in hypokalemia tubulopathy and deafness with variable severity. Although the underlying molecular mechanisms remain elusive, the modus operandi of K ir 5.1 is deeply rooted in its heteromeric association with K ir 4.1 ( KCNJ10 ) and K ir 4.2 ( KCNJ15 ). The ubiquitous expression of KCNJ16 and heterogeneous clinical picture point toward the importance of protein–protein interactions and membrane trafficking of the heteromeric channels involving K ir 5.1. Methods: In this study, we performed whole-exome sequencing for genetic screening. Functional studies were performed in Xenopus oocytes using two electrode voltage clamp recordings. Protein–protein interactions were determined by coimmunoprecipitation. Live-cell imaging was performed using confocal microscopy to visualize the subcellular localization of the fluorescence-tagged proteins using appropriate subcellular markers. Results: Here, we report four patients from three families with salt-losing tubulopathy, hypokalemia and acidosis secondary to pathogenic biallelic variants in KCNJ16 . In addition to two previously described variants with phenotypic consistency (R137C) or phenotypic variability (I132R+R176*), we report a variant (K48*-Y57*) possibly lacking deafness, expanding the variant spectrum. Our results demonstrate that, with the exception of premature termination fragments, pathogenic K ir 5.1 variants retain interactions with K ir 4.1 and K ir 4.2 but differentially impair membrane trafficking of the heteromeric channels, offering a molecular explanation for the observed clinical heterogeneity. Conclusions: Hypokalemia tubulopathy and deafness is a clinically heterogeneous disorder where the onset, presentation, and severity may be influenced by the type and location of the KCNJ16 variants. These variant-specific effects on channel assembly, trafficking, and residual function provide a mechanistic explanation for the broad spectrum of renal and auditory phenotypes and underscore the importance of molecular characterization for accurate diagnosis and personalized therapies.
- 10 August 2026
- Published by Wolters Kluwer Health in Kidney360
- Vol. 7 (10) , 2249-2262
Open AccessType, Location, and Zygosity of KCNJ16 Variants May Determine the Clinical Severity of Hypokalemia Tubulopathy and Deafness
Key Points: KCNJ16 variants cause clinically heterogeneous hypokalemic tubulopathy with variable onset, severity of acidosis, and possible sensorineural deafness. Pathogenic variants affect heteromerization, membrane trafficking, and activity of the resulting channels on the basis of the type and location of the variant. Background: The pivotal role of K ir 5.1 ( KCNJ16 ) in maintaining electrolyte and acid–base homeostasis has been demonstrated in animal studies and highlighted by the identification of disease-causing variants in KCNJ16 resulting in hypokalemia tubulopathy and deafness with variable severity. Although the underlying molecular mechanisms remain elusive, the modus operandi of K ir 5.1 is deeply rooted in its heteromeric association with K ir 4.1 ( KCNJ10 ) and K ir 4.2 ( KCNJ15 ). The ubiquitous expression of KCNJ16 and heterogeneous clinical picture point toward the importance of protein–protein interactions and membrane trafficking of the heteromeric channels involving K ir 5.1. Methods: In this study, we performed whole-exome sequencing for genetic screening. Functional studies were performed in Xenopus oocytes using two electrode voltage clamp recordings. Protein–protein interactions were determined by coimmunoprecipitation. Live-cell imaging was performed using confocal microscopy to visualize the subcellular localization of the fluorescence-tagged proteins using appropriate subcellular markers. Results: Here, we report four patients from three families with salt-losing tubulopathy, hypokalemia and acidosis secondary to pathogenic biallelic variants in KCNJ16 . In addition to two previously described variants with phenotypic consistency (R137C) or phenotypic variability (I132R+R176*), we report a variant (K48*-Y57*) possibly lacking deafness, expanding the variant spectrum. Our results demonstrate that, with the exception of premature termination fragments, pathogenic K ir 5.1 variants retain interactions with K ir 4.1 and K ir 4.2 but differentially impair membrane trafficking of the heteromeric channels, offering a molecular explanation for the observed clinical heterogeneity. Conclusions: Hypokalemia tubulopathy and deafness is a clinically heterogeneous disorder where the onset, presentation, and severity may be influenced by the type and location of the KCNJ16 variants. These variant-specific effects on channel assembly, trafficking, and residual function provide a mechanistic explanation for the broad spectrum of renal and auditory phenotypes and underscore the importance of molecular characterization for accurate diagnosis and personalized therapies.
- Open Access
Type, location and zygosity of KCNJ16 mutations may determine the clinical severity of Hypokalemic Tubulopathy and Deafness (HkTD)
The pivotal role of K ir 5.1 ( KCNJ16 ) in maintaining electrolyte and acid-base homeostasis was demonstrated by animal studies and highlighted by the identification of disease-causing mutations in KCNJ16 resulting in a complex tubulopathy with variable severity. Although the underlying molecular mechanisms remain elusive, the modus operandi of K ir 5.1 is rooted in its heteromeric association with K ir 4.1 ( KCNJ10 ) and K ir 4.2 ( KCNJ15 ). The ubiquitous expression of KCNJ16 and the heterogenous clinical picture point towards the importance of protein-protein interactions and membrane trafficking of the heteromeric channels involving K ir 5.1. Alongside a retrospective report on the R137C variant, we describe a divergent clinical phenotype in a patient compound heterozygous for I132R and R176*. Moreover, we characterize a novel variant (homozygous for K48* and Y57*) whose clinical presentation coincides with the phenotype of the Kcnj16 -/- mouse model (lack of deafness). Functional studies, buttressed by biomolecular studies (imaging and Co-IPs) in mammalian cells emphasize that the type and location of the KCNJ16 mutations may determine their interaction, membrane localization, and consequently, channel function and the resulting clinical phenotype. Our study highlights the need for molecular understanding of the KCNJ16 variants to promote correct diagnosis and personalized therapies, especially those involving channel modulators.
Open AccessType, location and zygosity of KCNJ16 mutations may determine the clinical severity of Hypokalemic Tubulopathy and Deafness (HkTD)
The pivotal role of K ir 5.1 ( KCNJ16 ) in maintaining electrolyte and acid-base homeostasis was demonstrated by animal studies and highlighted by the identification of disease-causing mutations in KCNJ16 resulting in a complex tubulopathy with variable severity. Although the underlying molecular mechanisms remain elusive, the modus operandi of K ir 5.1 is rooted in its heteromeric association with K ir 4.1 ( KCNJ10 ) and K ir 4.2 ( KCNJ15 ). The ubiquitous expression of KCNJ16 and the heterogenous clinical picture point towards the importance of protein-protein interactions and membrane trafficking of the heteromeric channels involving K ir 5.1. Alongside a retrospective report on the R137C variant, we describe a divergent clinical phenotype in a patient compound heterozygous for I132R and R176*. Moreover, we characterize a novel variant (homozygous for K48* and Y57*) whose clinical presentation coincides with the phenotype of the Kcnj16 -/- mouse model (lack of deafness). Functional studies, buttressed by biomolecular studies (imaging and Co-IPs) in mammalian cells emphasize that the type and location of the KCNJ16 mutations may determine their interaction, membrane localization, and consequently, channel function and the resulting clinical phenotype. Our study highlights the need for molecular understanding of the KCNJ16 variants to promote correct diagnosis and personalized therapies, especially those involving channel modulators.
- Open Access
- 8 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0329388
Association of germline variants in the ZFX gene with primary hyperparathyroidism
Somatic variants in the ZFX gene have been found in human sporadic parathyroid adenomas. This gene encodes a transcriptional factor recently described as a transcriptional activator in multiple types of human tumors. We present the clinical and molecular characterization of three patients diagnosed with primary hyperparathyroidism (PHPT) who have germline variants in the ZFX gene. The first patient had a pathogenic missense variant (c.2321A > G; p.(Tyr774Cys)) in the heterozygous state. This patient exhibited PHPT along with ear, nose and forehead abnormalities. Additionally, she presented other characteristics seen in patients with pathogenic variants in the ZFX gene, such as hearing loss and multiple cutaneous nevi. The second and third patients had a missense variant of uncertain significance (c.1606C > T; p.(Arg536Cys)) and an in-frame insertion (c.452_460dup; p.(Gly151_Val153dup)) of uncertain significance, respectively, both in the heterozygous state. These patients had no hearing loss, cutaneous melanocytic nevi, or bone or facial deformities. ZFX may be one of the genes to be analyzed in women affected by PHPT with suspected genetic inheritance, especially if they have other features such as facial deformities, hearing loss, and cutaneous melanocytic nevi.
- 8 August 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (8) , e0329388
Open AccessAssociation of germline variants in the ZFX gene with primary hyperparathyroidism
Somatic variants in the ZFX gene have been found in human sporadic parathyroid adenomas. This gene encodes a transcriptional factor recently described as a transcriptional activator in multiple types of human tumors. We present the clinical and molecular characterization of three patients diagnosed with primary hyperparathyroidism (PHPT) who have germline variants in the ZFX gene. The first patient had a pathogenic missense variant (c.2321A > G; p.(Tyr774Cys)) in the heterozygous state. This patient exhibited PHPT along with ear, nose and forehead abnormalities. Additionally, she presented other characteristics seen in patients with pathogenic variants in the ZFX gene, such as hearing loss and multiple cutaneous nevi. The second and third patients had a missense variant of uncertain significance (c.1606C > T; p.(Arg536Cys)) and an in-frame insertion (c.452_460dup; p.(Gly151_Val153dup)) of uncertain significance, respectively, both in the heterozygous state. These patients had no hearing loss, cutaneous melanocytic nevi, or bone or facial deformities. ZFX may be one of the genes to be analyzed in women affected by PHPT with suspected genetic inheritance, especially if they have other features such as facial deformities, hearing loss, and cutaneous melanocytic nevi.
- 1 April 2024
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 17 (2) , e004336
Dilated Cardiomyopathy With Concomitant Salt-Losing Renal Tubulopathy Caused by Heterozygous RRAGD Gene Variant
- 1 April 2024
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 17 (2) , e004336
Dilated Cardiomyopathy With Concomitant Salt-Losing Renal Tubulopathy Caused by Heterozygous RRAGD Gene Variant
- 3 November 2023
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 161 (10) , 458-459
Hypercalcemia in patients with mutations in NR3C2 and SCNN1B
- 3 November 2023
- Published by Elsevier in Medicina Clínica (English Edition)
- Vol. 161 (10) , 458-459
Hypercalcemia in patients with mutations in NR3C2 and SCNN1B
- 16 August 2023
- Published by Elsevier in Medicina Clinica
- Vol. 161 (10) , 458-459
Hipercalcemia en pacientes con mutación en NR3C2 y SCNN1B
- 16 August 2023
- Published by Elsevier in Medicina Clinica
- Vol. 161 (10) , 458-459
Hipercalcemia en pacientes con mutación en NR3C2 y SCNN1B
- Open Access
- 30 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (9) , e0239965
Novel variant in the CNNM2 gene associated with dominant hypomagnesemia
The maintenance of magnesium (Mg2+) homeostasis is essential for human life. The Cystathionine-β-synthase (CBS)-pair domain divalent metal cation transport mediators (CNNMs) have been described to be involved in maintaining Mg2+ homeostasis. Among these CNNMs, CNNM2 is expressed in the basolateral membrane of the kidney tubules where it is involved in Mg2+ reabsorption. A total of four patients, two of them with a suspected disorder of calcium metabolism, and two patients with a clinical diagnosis of primary tubulopathy were screened for mutations by Next-Generation Sequencing (NGS). We found one novel likely pathogenic variant in the heterozygous state (c.2384C>A; p.(Ser795*)) in the CNNM2 gene in a family with a suspected disorder of calcium metabolism. In this family, hypomagnesemia was indirectly discovered. Moreover, we observed three novel variants of uncertain significance in heterozygous state in the other three patients (c.557G>C; p.(Ser186Thr), c.778A>T; p.(Ile260Phe), and c.1003G>A; p.(Asp335Asn)). Our study shows the utility of Next-Generation Sequencing in unravelling the genetic origin of rare diseases. In clinical practice, serum Mg2+ should be determined in calcium and PTH-related disorders.
- 30 September 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (9) , e0239965
Open AccessNovel variant in the CNNM2 gene associated with dominant hypomagnesemia
The maintenance of magnesium (Mg2+) homeostasis is essential for human life. The Cystathionine-β-synthase (CBS)-pair domain divalent metal cation transport mediators (CNNMs) have been described to be involved in maintaining Mg2+ homeostasis. Among these CNNMs, CNNM2 is expressed in the basolateral membrane of the kidney tubules where it is involved in Mg2+ reabsorption. A total of four patients, two of them with a suspected disorder of calcium metabolism, and two patients with a clinical diagnosis of primary tubulopathy were screened for mutations by Next-Generation Sequencing (NGS). We found one novel likely pathogenic variant in the heterozygous state (c.2384C>A; p.(Ser795*)) in the CNNM2 gene in a family with a suspected disorder of calcium metabolism. In this family, hypomagnesemia was indirectly discovered. Moreover, we observed three novel variants of uncertain significance in heterozygous state in the other three patients (c.557G>C; p.(Ser186Thr), c.778A>T; p.(Ile260Phe), and c.1003G>A; p.(Asp335Asn)). Our study shows the utility of Next-Generation Sequencing in unravelling the genetic origin of rare diseases. In clinical practice, serum Mg2+ should be determined in calcium and PTH-related disorders.
- Open Access
- 1 September 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (11)
Novel compound heterozygous mutations of CLDN16 in a patient with familial hypomagnesemia with hypercalciuria and nephrocalcinosis
Background: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is an autosomal recessive tubulopathy characterized by excessive urinary wasting of magnesium and calcium, bilateral nephrocalcinosis, and progressive chronic renal failure in childhood or adolescence. FHHNC is caused by mutations in CLDN16 and CLDN19, which encode the tight‐junction proteins claudin‐16 and claudin‐19, respectively. Most of these mutations are missense mutations and large deletions are rare.Methods: We examined the clinical and biochemical features of a Spanish boy with early onset of FHHNC symptoms. Exons and flanking intronic segments of CLDN16 and CLDN19 were analyzed by direct sequencing. We developed a new assay based on Quantitative Multiplex PCR of Short Fluorescent Fragments (QMPSF) to investigate large CLDN16 deletions.Results: Genetic analysis revealed two novel compound heterozygous mutations of CLDN16, comprising a missense mutation, c.277G>A; p.(Ala93Thr), in one allele, and a gross deletion that lacked exons 4 and 5,c.(840+25_?)del, in the other allele. The patient inherited these variants from his mother and father, respectively.Conclusions: Using direct sequencing and our QMPSF assay, we identified the genetic cause of FHHNC in our patient. This QMPSF assay should facilitate the genetic diagnosis of FHHNC. Our study provided additional data on the genotypic spectrum of the CLDN16 gene.
- 1 September 2020
- Published by Wiley in Molecular Genetics & Genomic Medicine
- Vol. 8 (11)
Open AccessNovel compound heterozygous mutations of CLDN16 in a patient with familial hypomagnesemia with hypercalciuria and nephrocalcinosis
Background: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is an autosomal recessive tubulopathy characterized by excessive urinary wasting of magnesium and calcium, bilateral nephrocalcinosis, and progressive chronic renal failure in childhood or adolescence. FHHNC is caused by mutations in CLDN16 and CLDN19, which encode the tight‐junction proteins claudin‐16 and claudin‐19, respectively. Most of these mutations are missense mutations and large deletions are rare.Methods: We examined the clinical and biochemical features of a Spanish boy with early onset of FHHNC symptoms. Exons and flanking intronic segments of CLDN16 and CLDN19 were analyzed by direct sequencing. We developed a new assay based on Quantitative Multiplex PCR of Short Fluorescent Fragments (QMPSF) to investigate large CLDN16 deletions.Results: Genetic analysis revealed two novel compound heterozygous mutations of CLDN16, comprising a missense mutation, c.277G>A; p.(Ala93Thr), in one allele, and a gross deletion that lacked exons 4 and 5,c.(840+25_?)del, in the other allele. The patient inherited these variants from his mother and father, respectively.Conclusions: Using direct sequencing and our QMPSF assay, we identified the genetic cause of FHHNC in our patient. This QMPSF assay should facilitate the genetic diagnosis of FHHNC. Our study provided additional data on the genotypic spectrum of the CLDN16 gene.
- 11 May 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , e2687-e2688
Response to Letter to the Editor: “Forty-One Individuals with Mutations in the AVP-NPII Gene Associated with Familial Neurohypophyseal Diabetes Insipidus
Alejandro García-Castaño, Leire Madariaga, Gustavo Pérez de Nanclares, Amaia Vela, Itxaso Rica, Sonia Gaztambide, Rosa Martínez, Idoia Martinez de LaPiscina, In
- 11 May 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (7) , e2687-e2688
Response to Letter to the Editor: “Forty-One Individuals with Mutations in the AVP-NPII Gene Associated with Familial Neurohypophyseal Diabetes Insipidus
Alejandro García-Castaño, Leire Madariaga, Gustavo Pérez de Nanclares, Amaia Vela, Itxaso Rica, Sonia Gaztambide, Rosa Martínez, Idoia Martinez de LaPiscina, In
- Open Access
- 13 February 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (4) , 1112-1118
Forty-One Individuals With Mutations in the AVP-NPII Gene Associated With Familial Neurohypophyseal Diabetes Insipidus
Context Familial neurohypophyseal diabetes insipidus is a rare disease produced by a deficiency in the secretion of antidiuretic hormone and is caused by mutations in the arginine vasopressin gene. Objective Clinical, biochemical, and genetic characterization of a group of patients clinically diagnosed with familial neurohypophyseal diabetes insipidus, 1 of the largest cohorts of patients with protein neurophysin II (AVP-NPII) gene alterations studied so far. Design The AVP-NPII gene was screened for mutations by PCR followed by direct Sanger sequencing in 15 different unrelated families from Spain. Results The 15 probands presented with polyuria and polydipsia as the most important symptoms at the time of diagnosis. In these patients, the disease was diagnosed at a median of 6 years of age. We observed 11 likely pathogenic variants. Importantly, 4 of the AVP-NPII variants were novel (p.(Tyr21Cys), p.(Gly45Ser), p.(Cys75Tyr), p.(Gly88Cys)). Conclusions Cytotoxicity seems to be due to consequences common to all the variants found in our cohort, which are not able to fold correctly and pass the quality control of the ER. In concordance, we found autosomal dominant familial neurohypophyseal diabetes insipidus in the 15 families studied.
- 13 February 2020
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 105 (4) , 1112-1118
Open AccessForty-One Individuals With Mutations in the AVP-NPII Gene Associated With Familial Neurohypophyseal Diabetes Insipidus
Context Familial neurohypophyseal diabetes insipidus is a rare disease produced by a deficiency in the secretion of antidiuretic hormone and is caused by mutations in the arginine vasopressin gene. Objective Clinical, biochemical, and genetic characterization of a group of patients clinically diagnosed with familial neurohypophyseal diabetes insipidus, 1 of the largest cohorts of patients with protein neurophysin II (AVP-NPII) gene alterations studied so far. Design The AVP-NPII gene was screened for mutations by PCR followed by direct Sanger sequencing in 15 different unrelated families from Spain. Results The 15 probands presented with polyuria and polydipsia as the most important symptoms at the time of diagnosis. In these patients, the disease was diagnosed at a median of 6 years of age. We observed 11 likely pathogenic variants. Importantly, 4 of the AVP-NPII variants were novel (p.(Tyr21Cys), p.(Gly45Ser), p.(Cys75Tyr), p.(Gly88Cys)). Conclusions Cytotoxicity seems to be due to consequences common to all the variants found in our cohort, which are not able to fold correctly and pass the quality control of the ER. In concordance, we found autosomal dominant familial neurohypophyseal diabetes insipidus in the 15 families studied.